| Date | Title | Description |
| 10.07.2024 | New health-focused generative AI company emerges from stealth with Houston office, $4M in funding | A new scalable biodata foundry startup has emerged from stealth with $4 million in investment funding and two new health care artificial intelligence tools. The company is co-located in Houston and Palo Alto, California.
Biostate AI was co-... |
| 29.11.2023 | Cradle raises $24m for GenAI biotech platform | |
| 14.02.2023 | Twist Bioscience Publishes Data on VHH Single Domain Antibody Discovery Using New Methodology on Optofluidic Platform | Demonstrates Ability to Generate Humanized PSMA-Specific VHH Single Domain Antibodies via Single B Cell Screening on the Beacon Platform
Twist Bioscience Corporation, a company enabling customers to succeed through its offering of high-qual... |
| 08.02.2023 | Twist Bioscience Announces Technology Early Access of Enhanced Whole Genome Sequencing Solution at AGBT | Twist Bioscience Corporation, a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, announced technology early access of the Twist enhanced Whole Genome Sequencing (eWGS) solu... |
| 10.01.2023 | Twist Bioscience and CENTOGENE Launch Three Panels to Advance Rare Disease and Hereditary Cancer Research and Support Diagnostics | Combining expertise to advance precision medicine, while enabling efficient and timely insights into the diagnosis of rare diseases and hereditary cancer around the world
Twist Bioscience Corporation, a company enabling customers to succeed... |
| 17.11.2022 | Startup Cradle Lets You Design Custom Proteins By Just Typing In A Prompt | Cradle Team at their site in the Netherlands.Cradle |
| 11.02.2022 | Twist Bioscience Announces Pricing of an Upsized $250 Million Public Offering of Common Stock | Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the pricing of an upsized, underwritten public offering of 4... |
| 04.02.2022 | Twist Bioscience : Reports First Quarter 2022 Financial Results - Form 8-K | Twist Bioscience Reports First Quarter 2022 Financial Results
-- Record Revenues of $42M; Increase of 49% over $28.2M in Fiscal 2021 --
-- Orders Increased 48% to $49.6M --
-- Increased Revenue Guidance for Fiscal 2022 --
SOUTH SAN FRANCISC... |
| 25.01.2022 | Reinet Investments S C A : Management Statement for the third quarter ended 31 December 2021 | COMPANY ANNOUNCEMENT FOR IMMEDIATE RELEASE
25 JANUARY 2022
MANAGEMENT STATEMENT FOR THE THIRD QUARTER ENDED 31 DECEMBER 2021
The Board of Reinet Investments Manager S.A. announces the results of Reinet Investments S.C.A. for the quarter end... |
| 22.03.2021 | Twist Bioscience Functional GLP-1R Antibodies Identified From Its Proprietary Synthetic DNA GPCR Libraries Demonstrate Potent Blood Glucose Control | SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Mar 22, 2021--
Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced... |
| 15.03.2021 | Twist Bioscience Begins Shipping of Synthetic RNA Controls for B.1.351 and P.1 Variants | SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Mar 15, 2021--
Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced... |
| 09.03.2021 | Twist Bioscience Named to Fast Company’s Annual List of the World’s Most Innovative Companies for 2021 | SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Mar 9, 2021--
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, has been named t... |
| 11.09.2020 | Bioeconomy Powerhouse Berkeley Lights Nearly Triples Since IPO, Now Valued At $3.9 Billion | How small groups of live cells can be plucked like needles from a haystack: An assay performed by ... [+] the University of Queensland on a Berkeley Lights' NanoPen™ for their COVID-19 treatment research. Berkeley Lights, Inc. |
| 09.09.2020 | Synthetic Biology Startups Raised $3 Billion In The First Half Of 2020 | (Getty Images/Luis Alvarez) |
| 15.07.2020 | IndieBio’s Arvind Gupta Joins Mayfield, Will Lead New Alliance Using Capitalism And Biology To Do Good In The World | The Genesis Consortium will elevate their work to transform human and planetary health with engineering biology |
| 23.05.2020 | Mike Kamdar, The Future Of DNA Writing, And The Business Of Biology | With a new way to write DNA, Mike Kamdar and his team at Molecular Assemblies are poised to disrupt just about any industry you can imagine. |
| 02.04.2020 | ARCH Venture, Flagship Pioneering close funds worth nearly $2.6B | ARCH said it would use its two funds to invest in early-stage companies. Although it plans to frequently draw from both to invest in a single company, the overage fund will be used in fewer deals that require larger investments.
“ARCH is st... |
| 28.03.2020 | Is Coronavirus In The NYC Subway? How Swabbing Doors And Trains Is Shaping The Fight Against COVID-19 | New Yorkers know the subway can be nasty, but COVID-19 has made riding the rails feel even dicier ... [+] than usual. Here's how we test for pathogens in public places, and what it says about the course we should follow. KE ATLAS on Unsplas... |
| 17.01.2020 | Deep tech VCs on what they view as some of the most impactful young startups right now | During this week’s Democratic debate, there was a lot of talk, unsurprisingly, about ensuring the future of this country’s children and grandchildren. Climate change was of particular interest to billionaire Tom Steyer, who said repeatedly ... |
| 13.03.2018 | Twist Bioscience Completes $50 Million Financing to Fuel Advancement of Digital Storage in DNA and Drug Discovery | - |
| 16.10.2017 | Illumina Ventures Founder talks about investment priorities for first $230M fund (Updated) | Illumina Ventures Founder Nicholas Naclerio responded to questions about its investment strategy and funding priorities in an email.
He said the fund invests in life science tools, clinical diagnostics, therapeutics, and other opportunities... |
| 15.06.2017 | Term Sheet — Thursday, June 15 | GREEDY BASTARDS
Good morning.
Paid Content What you need to know about growing cyberattacks From ExtraHop
• That price would be more than double Slack’s latest private valuation from 2016.
• Amazon is not known for its monster acquisitions.... |
| 15.06.2017 | Twist Bioscience Announces $27M Financing |
SAN FRANCISCO, CA, Twist Bioscience, a provider of DNA synthesis, has raised $27 million in funding.
>> Click here for more funding data on Twist Bioscience
>> To export Twist Bioscience funding data to PDF and Excel, click ... |
| 14.06.2017 | Twist Bioscience Raises Additional $27M in Venture Capital Funding | Twist Bioscience Corporation, a San Francisco, CA-based developer of a proprietary semiconductor-based synthetic DNA manufacturing process, raised an additional $27m in venture capital financing.
This close, combined with the $33m announced... |
| 28.03.2017 | Papiernik named chairman at Sofinnova Partners; Cara shares surge on positive data for uremic pruritus | Antoine Papiernik
→ Twenty years after joining Sofinnova Partners in Paris, Antoine Papiernik is taking the chairman’s post. Papiernik is well known in VC circles on both sides of the Atlantic, and played a leading role inve... |
| 27.03.2017 | Twist Bioscience Raises Additional $33M in Funding | Twist Bioscience, a San Francisco, CA-based developer of a DNA synthesis process, raised an additional $33m in funding.
The backers were not disclosed.
The company, which has raised a total of $166m, intends to use the funds to further acce... |
| 04.09.2016 | The biotech empires of Silicon Valley and Europe | Bérénice Magistretti Contributor
Bérénice Magistretti is a Swiss freelance writer based in San Francisco. She focuses on startups in Saudi Arabia, Switzerland and emerging markets.
More posts by this contributor
Disrupting the world of scie... |
| 02.05.2016 | Can DNA become the future of digital storage? Microsoft is betting on it | It’s popular these days to decry the superiority of machines over biology. Each time some AI-infused algorithm defeats a human at a board game, people gasp and wring their hands in despair. But these are really straw-man contests. Evolution... |
| 29.04.2016 | Microsoft Acquires 10 Million Strands Of DNA For Digital Storage Experiment | Anu Passary, Tech Times 29 April 2016, 07:04 am
Microsoft is poised to acquire 10 million strands of DNA from Twist Bioscience which the company will possibly use for experiments in digital storage.
Twist Bioscience is a San Francisco-based... |
| 27.04.2016 | Microsoft experiments with DNA storage: 1,000,000,000 TB in a gram | reader comments 129 with 82 posters participating
Share this story
Share on Facebook
Share on Twitter
Share on Reddit
Microsoft is buying ten million strands of DNA from biology startup Twist Bioscience to investigate the use of genetic mat... |
| 27.04.2016 | Genetics startup Twist Bioscience is working with Microsoft to store the world’s data in DNA | Twist Bioscience, a startup making and using synthetic DNA to store digital data, just struck a contract with Microsoft and the University of Washington to encode vast amounts of information on synthetic genes.
Big data means business and t... |
| 19.04.2016 | On heels of Genome Compiler buy, Twist Bioscience raises small round | Twist Bioscience’s platform centers around scaling DNA synthesis, building genetic sequences out at a fraction of the price of what they’ve historically cost.
“Twist’s beta program is progressing well and our first customer shipments are un... |
| 19.01.2016 | Scaling DNA synthesis 10,000-fold: Twist Bioscience raises $81M | While it’s already working with companies in the fields of industrial chemicals and data storage, Twist Bioscience plans to announce new partnerships in the pharmaceutical industry in the coming months, CEO Emily Leproust said in a statemen... |
| 19.01.2016 | Twist Bioscience Completes $61M Series D Financing | Twist Bioscience, a San Francisco, CA-based company accelerating science and innovation through DNA synthesis, completed a $61m Series D financing.
Backers included ARCH Overage Fund, Merieux Developpement, Cormorant Asset Management, Fidel... |
| 19.01.2016 |
Illumina Makes Another Investment In Twist Bioscience
| San Diego-based life sciences maker Illumina has participated in another investment round for San Francisco-based DNA synthesis startup Twist Bioscience, in a new Series D funding for that company. Twist announced a $61M Series D financing ... |
| 28.09.2015 | Synthetic Biology Is Not Just Good, It’s Good For You | Emily Leproust Contributor
Emily Leproust is CEO of Twist Bioscience.
More posts by this contributor
Beyond The $1K Genome: DNA ‘Writing’ Comes Next
Synthetic biology (synbio for short) is a term that circulates freely through the tech worl... |
| 18.09.2015 | Beyond The $1K Genome: DNA ‘Writing’ Comes Next | Emily Leproust Contributor
Emily Leproust is CEO of Twist Bioscience.
More posts by this contributor
Beyond The $1K Genome: DNA ‘Writing’ Comes Next
The “$1,000 genome” has been one of the most visible tech goals in the last 10 years, even ... |
| 15.06.2015 | Сделки недели: Новости российского венчурного рынка с 8 по 14 июня Статьи редакции | Еженедельная подборка новостей о российском венчурном рынке за прошедшие семь дней.
8 июня
В Казани открылся региональный офис акселератора «МетаБета» на базе технопарка «Навигатор Кампус». Его возглавит региональный руководитель компании А... |
| 10.06.2015 | Twist Bioscience Completes $37M Series C Financing | Twist Bioscience, a San Francisco, CA-based company focused on synthetic DNA, completed a $37m Series C financing.
The round was led by Illumina, Inc., with participation from new investors Fidelity Management and Research Company and Fores... |
| 09.06.2015 |
Illumina Backs Twist Bioscience
| San Diego-based life sciences equipment maker Illumina is the lead investor in San Francisco-based Twist Bioscience, a developer of a synthetic DNA manufacturing technology. Twist Bioscience said it raised $37M in a Series C, led by Illumin... |
| 30.09.2014 | Twist Bioscience Secures up to $10M Loan Facility with Silicon Valley Bank | Twist Bioscience, a San Francisco, CA-based provider of a synthetic DNA platform, secured an up to $10m loan facility with Silicon Valley Bank.
Under the terms of the agreement, Twist will be able to draw upon a portion of the loan immediat... |
| 27.05.2014 | Twist Bioscience Raises $26M in Series B Financing | Twist Bioscience, a San Francisco, CA-based developer of a semiconductor-based synthetic DNA manufacturing process, raised $26m in Series B financing.
The round was led by Nick and Joby Pritzker, through their family’s firm Tao Invest, with... |
| 27.05.2014 | Twist Bioscience Secures $31.1M in Series B |
SAN FRANCISCO, CA, Twist Bioscience today announced that it raised $26 million in a Series B financing.
>> Click here for more funding data on Twist Bioscience
>> To export Twist Bioscience funding data to PDF and Excel, cli... |
| - | How oligos changed the world | This article is adapted from the original, which first appeared on the Twist Bioscience blog.
Oligonucleotides (or oligos for short) are one of the most important tools in modern day molecular biology. Without oligos, today’s biotechnology,... |
| - | Scaling DNA synthesis 10,000-fold: Twist Bioscience raises $81M | A traditional 96-well plate used for DNA synthesis. Twist Bioscience’s plates are the same size, but have 10,000 microwells.
Twist Bioscience is upping the game of DNA synthesis on the 96-well plate: It has created – and is commercializing ... |
| - | Illumina Ventures Founder talks about investment priorities for first $230M fund (Updated) | Early stage genomics businesses are the focus of Illumina Ventures’ first fund. Launched last year as the investment arm of biotech business Illumina, the firm has raised $230 million for the first fund, according to a news release.
So far ... |
| - | Twist Bioscience to Highlight Genotyping by Sequencing and Methylation Solution During AGBT | SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Mar 1, 2021--
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced ... |
| - | On heels of Genome Compiler buy, Twist Bioscience raises small round | Bay Area DNA synthesis startup Twist Bioscience just raised a small round of funding: It just brought in $2.6 million from 46 investors, according to a regulatory filing.
This comes in sharp contrast to the $81 million it raised just this p... |
| - | ARCH Venture, Flagship Pioneering close funds worth nearly $2.6B | Two large venture capital firms have raised nearly $2.6 billion that they plan to invest in life sciences startups, they said in announcements Thursday.
Cambridge, Massachusetts-based Flagship Pioneering said it had closed a $1.1 billion ca... |
| - | Unpacking the CRISPR toolbox | This article is adapted from the original, which first appeared on the Twist Bioscience blog.
CRISPR, or clustered regularly interspaced short palindromic repeats, describes a genetic motif in bacterial and archaeal genomes that encodes a s... |
